Sign up to save your podcasts
Or
Share Cost-Effectiveness of Aducanumab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cost-Effectiveness of Aducanumab
Dr. Brian Callaghan discusses the AAN's comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer's disease.
View all episodes
By American Academy of Neurology
4.8
132132 ratings
Dr. Brian Callaghan discusses the AAN's comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer's disease.
More shows like Neurology Minute
View all
NEJM This Week
321 Listeners
JAMA Clinical Reviews
504 Listeners
Neurology® Podcast
299 Listeners
Practical Neurology Podcast
53 Listeners
Mayo Clinic Talks
298 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
JAMA Neurology Author Interviews
16 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
Neurology Today in 5
24 Listeners
Annals On Call Podcast
194 Listeners
JAMA Medical News
94 Listeners
The Clinical Problem Solvers
518 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Neurology Exam Prep Podcast
189 Listeners
Continuum Audio
80 Listeners